BRPI0916936A8 - composições faramacêuticas e métodos para produzir baixas concentrações de impureza das mesmas. - Google Patents

composições faramacêuticas e métodos para produzir baixas concentrações de impureza das mesmas.

Info

Publication number
BRPI0916936A8
BRPI0916936A8 BRPI0916936A BRPI0916936A BRPI0916936A8 BR PI0916936 A8 BRPI0916936 A8 BR PI0916936A8 BR PI0916936 A BRPI0916936 A BR PI0916936A BR PI0916936 A BRPI0916936 A BR PI0916936A BR PI0916936 A8 BRPI0916936 A8 BR PI0916936A8
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
low impurity
producing low
impurity concentrations
Prior art date
Application number
BRPI0916936A
Other languages
English (en)
Inventor
Krishna Gopal
Flood Keith
Ramakrishna Kornepati
Ding Min
Motheram Rajeshwar
Original Assignee
Hospira Inc
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916936(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Inc, The Medicines Co filed Critical Hospira Inc
Publication of BRPI0916936A2 publication Critical patent/BRPI0916936A2/pt
Publication of BRPI0916936A8 publication Critical patent/BRPI0916936A8/pt
Publication of BRPI0916936B1 publication Critical patent/BRPI0916936B1/pt
Publication of BRPI0916936B8 publication Critical patent/BRPI0916936B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0916936A 2008-08-01 2009-07-29 composições farmacêuticas, uso de clevidipina e método de reduzir impurezas. BRPI0916936B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8559708P 2008-08-01 2008-08-01
US61/085,597 2008-08-01
US9377208P 2008-09-03 2008-09-03
US61/093,772 2008-09-03
PCT/US2009/052127 WO2010014727A1 (en) 2008-08-01 2009-07-29 Pharmaceutical compositions and methods for producing low impurity concentrations of the same

Publications (4)

Publication Number Publication Date
BRPI0916936A2 BRPI0916936A2 (pt) 2017-05-23
BRPI0916936A8 true BRPI0916936A8 (pt) 2017-12-05
BRPI0916936B1 BRPI0916936B1 (pt) 2020-08-04
BRPI0916936B8 BRPI0916936B8 (pt) 2021-05-25

Family

ID=41610719

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916936A BRPI0916936B8 (pt) 2008-08-01 2009-07-29 composições farmacêuticas, uso de clevidipina e método de reduzir impurezas.

Country Status (20)

Country Link
US (6) US20100113534A1 (pt)
EP (2) EP2719386A1 (pt)
JP (1) JP5674660B2 (pt)
KR (1) KR101772602B1 (pt)
CN (1) CN102170786B (pt)
AU (1) AU2009276560B2 (pt)
BR (1) BRPI0916936B8 (pt)
CA (2) CA3108961C (pt)
CY (1) CY1116490T1 (pt)
DK (1) DK2320740T3 (pt)
EA (1) EA021336B1 (pt)
ES (1) ES2468837T3 (pt)
HR (1) HRP20140434T1 (pt)
MX (1) MX2011001240A (pt)
NZ (1) NZ591205A (pt)
PL (1) PL2320740T3 (pt)
PT (1) PT2320740E (pt)
SI (1) SI2320740T1 (pt)
SM (1) SMT201400081B (pt)
WO (1) WO2010014727A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108961C (en) 2008-08-01 2024-07-02 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low concentrations of impurities thereof
WO2012051116A1 (en) * 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN103134891A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 一种丁酸氯维地平含量和有关物质的测定方法
CN110840890A (zh) 2012-10-26 2020-02-28 凯西制药公司 用于在心力衰竭中控制血压和减轻呼吸困难的方法
CN103417539B (zh) * 2013-08-22 2015-11-25 北京蓝丹医药科技有限公司 一种丁酸氯维地平药物组合物
CN104974042A (zh) * 2014-04-09 2015-10-14 上海信谊金朱药业有限公司 化合物的制备方法
CN104974043A (zh) * 2014-04-09 2015-10-14 上海信谊金朱药业有限公司 丁酸氯维地平的杂质化合物的制备方法
MX385243B (es) * 2014-05-19 2025-03-14 The Medicines Co Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
CN104458937B (zh) * 2014-11-20 2017-02-22 北京京科泰来科技有限公司 一种丁酸氯维地平脂肪乳有关物质检测方法
CN104597192B (zh) * 2014-12-31 2016-08-24 武汉科福新药有限责任公司 一种丁酸氯维地平及其制剂中有关物质的检测方法
CN105853353A (zh) * 2015-01-20 2016-08-17 江苏正大丰海制药有限公司 一种氯维地平脂肪乳注射液的制备方法
CN107362139B (zh) * 2017-08-29 2020-11-03 辅必成（上海）医药科技有限公司 一种丁酸氯维地平的乳剂注射液
US20200316043A1 (en) * 2017-12-20 2020-10-08 Aurobindo Pharma Ltd. Pharmaceutical composition comprising clevidipine and process for preparation thereof
CN109956943B (zh) * 2019-04-18 2021-07-20 合肥合源药业有限公司 一种二氢吡啶类药物中脱羧缩合杂质及其制备、控制方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150744A (en) * 1976-02-27 1979-04-24 Smith & Nephew Pharmaceuticals Ltd. Packaging
DE3532129A1 (de) * 1985-09-10 1987-03-12 Bayer Ag Ss-carotin enthaltende gelatine
SE9303657D0 (sv) * 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) * 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
EP1165091B1 (en) 1999-03-31 2005-01-26 PHARMACIA & UPJOHN COMPANY Pharmaceutical emulsions for retroviral protease inhibitors
US6956048B2 (en) * 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6680334B2 (en) * 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
JP2003104888A (ja) 2001-09-28 2003-04-09 Taiyo Yakuhin Kogyo Kk ジヒドロピリジン誘導体の錠剤
ATE375349T1 (de) * 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
US20050186230A1 (en) 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
US20080095841A1 (en) 2004-10-06 2008-04-24 Eisai R&D Management Co., Ltd. Pharmaceutical Composition, Method for Producing the Same, and Method for Stabilizing Dihydropyridine Compound in the Pharmaceutical Composition
US20100016378A1 (en) * 2005-04-28 2010-01-21 Toshio Suzuki Method of preventing dihydropyridine compound from degradation
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006275784A1 (en) * 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
CA3108961C (en) 2008-08-01 2024-07-02 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low concentrations of impurities thereof
CA2734780C (en) 2008-08-22 2016-07-05 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
CN101766568A (zh) 2008-12-31 2010-07-07 北京利乐生制药科技有限公司 一种含有氯维地平的乳剂及其制备工艺和用途
CN101780036B (zh) 2010-03-30 2011-11-16 武汉武药科技有限公司 丁酸氯维地平脂微球注射液及其制备方法
WO2012051116A1 (en) 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents

Also Published As

Publication number Publication date
BRPI0916936B1 (pt) 2020-08-04
EA021336B1 (ru) 2015-05-29
JP5674660B2 (ja) 2015-02-25
CA3108961C (en) 2024-07-02
CY1116490T1 (el) 2017-03-15
BRPI0916936A2 (pt) 2017-05-23
PL2320740T3 (pl) 2014-09-30
CA2732760A1 (en) 2010-02-04
EP2320740A1 (en) 2011-05-18
US20250213540A1 (en) 2025-07-03
AU2009276560A1 (en) 2010-02-04
US20120322835A1 (en) 2012-12-20
ES2468837T3 (es) 2014-06-17
CN102170786B (zh) 2015-05-27
EP2719386A1 (en) 2014-04-16
EP2320740A4 (en) 2011-11-30
US20190091212A1 (en) 2019-03-28
DK2320740T3 (da) 2014-06-30
HRP20140434T1 (hr) 2014-08-01
US20100113534A1 (en) 2010-05-06
BRPI0916936B8 (pt) 2021-05-25
CA3108961A1 (en) 2010-02-04
KR20110060889A (ko) 2011-06-08
KR101772602B1 (ko) 2017-08-29
PT2320740E (pt) 2014-06-12
NZ591205A (en) 2012-11-30
AU2009276560B2 (en) 2015-04-16
SI2320740T1 (sl) 2014-08-29
US11058672B2 (en) 2021-07-13
CN102170786A (zh) 2011-08-31
JP2011529900A (ja) 2011-12-15
MX2011001240A (es) 2011-08-12
EA201170289A1 (ru) 2011-10-31
EP2320740B1 (en) 2014-03-26
US20140005233A1 (en) 2014-01-02
US20220000849A1 (en) 2022-01-06
WO2010014727A1 (en) 2010-02-04
SMT201400081B (it) 2014-09-08

Similar Documents

Publication Publication Date Title
BRPI0916936A2 (pt) composições faramacêuticas e métodos para produzir baixas concentrações de impureza da mesmas.
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI1010772A2 (pt) composto,e, composição farmacêutica.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0923702A2 (pt) composições de inseticida estáveis e métodos para produzir as mesmas
BRPI0718688A2 (pt) Composições de baixa irritação e métodos para preparar as mesmas.
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
PT3178490T (pt) Composições de proteína f de rsv e métodos para produção das mesmas
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
BRPI0916689A2 (pt) composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI1005919A2 (pt) composição imunogênica
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: HOSPIRA, INC (US) , CHIESI FARMACEUTICI S.P.A. (IT

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF